Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

about

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

Item

http://www.wikidata.org/entity/Q48252129

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Abatacept used in combination ...... ls and the real-world setting.

@en

Abatacept used in combination ...... ls and the real-world setting.

@nl

type

Item

label

Abatacept used in combination ...... ls and the real-world setting.

@en

Abatacept used in combination ...... ls and the real-world setting.

@nl

prefLabel

Abatacept used in combination ...... ls and the real-world setting.

@en

Abatacept used in combination ...... ls and the real-world setting.

@nl

P1476

Abatacept used in combination ...... als and the real-world setting

@en

P2093

Andrea Rubbert-Roth

http://www.w3.org/2001/XMLSchema#string

Christiane Rauch

http://www.w3.org/2001/XMLSchema#string

Eugen Feist

http://www.w3.org/2001/XMLSchema#string

Harald Burkhardt

http://www.w3.org/2001/XMLSchema#string

Juergen Rech

http://www.w3.org/2001/XMLSchema#string

Klaus Krüger

http://www.w3.org/2001/XMLSchema#string

Reinhard E Voll

http://www.w3.org/2001/XMLSchema#string

Yedid Elbez

http://www.w3.org/2001/XMLSchema#string

P2860

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

Abatacept.

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.

Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

P2888

s13075-017-1488-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-017-1488-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rieke Alten

P577

2018-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100169577

http://www.w3.org/2001/XMLSchema#string

P698

29329602

http://www.w3.org/2001/XMLSchema#string

P932

5795278

http://www.w3.org/2001/XMLSchema#string